Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Return on Capital Employed (2018 - 2025)

Historic Return on Capital Employed for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to 0.89%.

  • X4 Pharmaceuticals' Return on Capital Employed fell 7400.0% to 0.89% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.89%, marking a year-over-year decrease of 7400.0%. This contributed to the annual value of 0.32% for FY2024, which is 5200.0% up from last year.
  • X4 Pharmaceuticals' Return on Capital Employed amounted to 0.89% in Q3 2025, which was down 7400.0% from 1.12% recorded in Q2 2025.
  • In the past 5 years, X4 Pharmaceuticals' Return on Capital Employed ranged from a high of 0.08% in Q1 2025 and a low of 1.33% during Q3 2022
  • Moreover, its 5-year median value for Return on Capital Employed was 0.78% (2023), whereas its average is 0.72%.
  • Over the last 5 years, X4 Pharmaceuticals' Return on Capital Employed had its largest YoY gain of 10100bps in 2025, and its largest YoY loss of -9800bps in 2025.
  • Over the past 5 years, X4 Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.81% in 2021, then increased by 4bps to 0.78% in 2022, then fell by 0bps to 0.78% in 2023, then skyrocketed by 64bps to 0.28% in 2024, then tumbled by -217bps to 0.89% in 2025.
  • Its Return on Capital Employed was 0.89% in Q3 2025, compared to 1.12% in Q2 2025 and 0.08% in Q1 2025.